March 19th 2023
Vorasidenib met its prespecified progression-free survival endpoint in the phase 3 INDIGO trial.
Oncology Nurses Need Better Resources to Help Patients With Mental Health ProblemsOctober 4th 2022
Although oncology nurses are trained to show empathy and offer support, they lack the resources to adequately care for patients with acute mental health problems.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for PatientsSeptember 28th 2022
Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Are Oncology Nurses Underutilized in Positively Affecting the Opioid Epidemic?July 7th 2022
Gretchen McNally PhD, ANP-BC, AOCNP, discusses the potential impact advanced practice providers and nurses could have in the opioid pandemic if the correct educational opportunities were available.
Experts Make the Case for Buprenorphine Use in Cancer-Related Pain ManagementJune 28th 2022
Mary Lynn McPherson, PharmD, BCPS, FAAHPM, and Amy A. Case, MD, FAAHPM, argue that buprenorphine should play a larger role in cancer-related pain management because of its unique pharmacology and consequent safety profile.
FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E–Mutated Solid TumorsJune 23rd 2022
The FDA approval of dabrafenib plus trametinib for BRAF V600E–mutated unresectable or metastatic solid tumors highlights a potential need for routine BRAF testing in clinical practice, experts say.
Temferon Is a Viable Treatment Option in Newly Diagnosed GlioblastomaApril 16th 2022
Preliminary findings from the phase 1/2a TEM-GBM study highlight the potential utility of temferon, genetically modified Tie2-expressing monocytes targeting interferon a2 in treating patients with glioblastoma.
Adjuvant Neratinib Does Not Improve Overall Survival in Glioblastoma, Yet May Offer Benefit for EGFR+ SubsetMarch 10th 2022
Although adjuvant neratinib was not found to improve progression-free or overall survival across a population of patients with glioblastoma, the agent yielded promising progression-free survival rates in a subset of patients with EGFR-positive disease.
FDA Approves Bevacizumab Biosimilar for 5 Cancer TypesJune 28th 2019
The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
Radiation Treatment May Impair Recent Memory in Pediatric Patients With Brain TumorsSeptember 24th 2018
Children with pediatric posterior fossa tumors like medulloblastoma who are treated with radiotherapy may be less likely to recall specific details of events that occurred after treatment compared with events that happened before, according to study results published in the Journal of Neuroscience.